TCR2 Therapeutics' GAAP loss for 9M 2021 was $72.068 million, up 48.1% from $48.673 million in the prior year.
TCR2 Therapeutics' GAAP loss for 9M 2021 was $72.068 million, up 48.1% from $48.673 million in the prior year.
Financial results
TCR2 Therapeutics' GAAP loss for 9M 2021 was $72.068 million, up 48.1% from $48.673 million in the prior year. Source: 
investors.tcr2.com
investors.tcr2.com News feed
English (US) 